Marealis’ novel shrimp peptide gains EFSA green light
22 May 2018 --- The European Food Safety Authority (EFSA) has approved an application for the novel food status of a shrimp peptide concentrate, meaning that the ingredient can now be utilized in EU supplement applications. The application was made by the company Medfiles Ltd. on behalf of Marealis, a developer of science-backed nutraceuticals. The supplements will be marketed to those who want to address the problem of prehypertension in the Marealis product, PreCardix. “The EFSA approval means that we will now be able to start working on commercialization in Europe. It also means that all our regulatory processes are completed with huge success – receiving approvals from Health Canada, FDA and EFSA,” Andreas Semmingsen, Head of Market and Finance at Marealis tells NutritionInsight. “We have strong documentation showing a significant blood pressure lowering effect from using PreCardix. In Canada, where we just started sales, we have an approval to use the following health claim: ‘Helps to Following a request from the European Commission, the EFSA panel of Dietetic Products, Nutrition and Allergies (NDA) were asked to deliver a scientific opinion on shrimp peptide concentrate as a novel food (NF). Marealis provided scientific studies and data on the shrimp peptides health benefits. During the process, one key concern was the potential astaxanthin content of the product because shrimps are a natural source of this carot However, the shrimp peptides were approved to be marketed to adults at the maximum proposed level of intake of 1,200 mg a day. There were no concerns with regard to genotoxicity, the available human data do not raise safety concerns and there were no considered adverse effects for oral toxicity. Marealis appear confident on the future path of the shrimp peptide as a novel food ingredient, with other geographic areas delivering positive results: “We just started sales in Canada, which was a huge milestone for us. We will now start to work on commercialization of PreCardix in Norway. We hope to be in the Norwegian supplement market by the end of 2018. Our plan is to start with the Norwegian marked and expand to other European countries eventually.” Marealis is a Norwegian marine biotechnology company focusing on the development of novel bioactive peptides derived from sustainable sources of the Arctic Ocean. By Laxmi Haigh To contact our editorial team please email us at editorial@cnsmedia.com
Related ArticlesHealth & Nutrition News Supporting cognition: Blueberries may promote neuronal activation to help ward off dementia10 Jan 2019 --- Blueberry supplementation may benefit older adults at increased risk of dementia, according to new research. In a randomized, double-blind, placebo-controlled trial, researchers detected altered neuronal activation following blueberry supplementation in older adults with Mild Cognitive Impairment (MCI). The results suggest that anthocyanin-rich berries may hold promise in supporting cognitive functions. Health & Nutrition News Low salt diet benefits women more than men, study suggests12 Dec 2018 --- Following a low salt diet is more effective in lowering blood pressure in women than men, according to a study from the Medical College of Georgia at Augusta University. Even though the levels of salt retention are similar in both sexes, the researchers found that blood pressure was more elevated in females. Food Ingredients News Vegan diet more beneficial to heart health than AHA recommended diet10 Dec 2018 --- A comparative study by the American Heart Association (AHA) has shown that a vegan diet is more effective in reducing the risk of coronary heart disease than the AHA recommended diet. Health & Nutrition News Black cumin: Botanic Innovations on protecting the seed oil supply chain29 Nov 2018 --- The quick growth of black cumin has increased the risk of intentional or unintentional adulteration, notes supplier Botanic Innovations on the botanical which ranks among The American Botanical Council’s top 25 fastest growing herbal ingredients of 2017. Regulatory News Oleic acid CHD claims success: US FDA approves qualified claim petition on high level foods20 Nov 2018 --- The US Food and Drug Administration (FDA) has responded positively to a petition for a new qualified health claim for edible oils containing oleic acid. As a result, products with an oleic acid content upward of 70 percent, such as certain olive, canola and sunflower oils, can be labeled as carrying cardiovascular benefits, but only when replacing heart-damaging saturated fat. More Articles |
.jpg)
